Welcome to our dedicated page for Ascentage Pharma Group International SEC filings (Ticker: AAPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ascentage Pharma Group International furnishes SEC filings as a foreign private issuer reporting under Form 6-K and indicating annual reporting on Form 20-F. The filings document press releases and Hong Kong Stock Exchange announcements for annual results, oncology pipeline updates, clinical and preclinical presentation materials, and changes in corporate administration.
The company’s filing record also includes Hong Kong annual report and environmental, social and governance materials, annual general meeting notices, proxy forms, director re-election matters, general mandates to issue or repurchase shares, and supplemental equity-incentive grant proposals under its RSU and post-IPO share option schemes.
Ascentage Pharma Group International has changed its principal place of business in Hong Kong. Effective April 1, 2026, the address is now Unit 906, 9/F., Haleson Building, 1 Jubilee Street, Central, Hong Kong.
The change is reported on a Form 6-K, which furnishes the related Hong Kong announcement and is signed by Chief Executive Officer Dr. Dajun Yang.
Ascentage Pharma reported unaudited 2025 results showing strong product momentum but much heavier losses. Revenue was RMB574.1 million (US$82.1 million), down from RMB980.7 million in 2024 because the prior year included RMB678.4 million of one‑off intellectual property income. Core drug sales improved: Olverembatinib revenue in China rose 80.6% to RMB435.3 million (US$62.2 million), and newly launched Lisaftoclax contributed RMB70.6 million (US$10.1 million) in its first months on the market. Investment in growth was substantial, with selling and distribution expenses up 80.4% and research and development expenses up 20.1% to RMB1,137.4 million (US$162.7 million). As a result, net loss widened sharply to RMB1,243.0 million (US$177.7 million) from RMB405.7 million. Liquidity strengthened, as cash and bank balances nearly doubled to RMB2,470.1 million (US$353.2 million), funded by a U.S. Nasdaq IPO raising US$132.5 million and a Hong Kong follow‑on offering raising US$190.1 million. Clinically, the company advanced nine registrational trials across Olverembatinib, Lisaftoclax and APG‑2449 and secured FDA and EMA clearances for additional Phase III studies, while APG‑3288, a BTK degrader, received IND clearances in the U.S. and China.
ASCENTAGE PHARMA GROUP INTERNATIONAL Chief Medical Officer Yifan Zhai filed an initial ownership report listing existing holdings, rather than new trades. The filing shows options and restricted share units over ordinary shares, vesting in four equal parts on each of 11/26/2026, 2027, 2028 and 2029, plus direct and indirect ordinary share positions held through a trust, spouse and HealthQuest Pharma Limited.
ASCENTAGE PHARMA GROUP INTERNATIONAL director Wei Ren has filed an initial ownership report on Form 3, detailing current equity holdings in the company. The filing shows stock options over 18,850 Ordinary Shares at an exercise price of $8.1400 per share, expiring on November 26, 2035. These options vest in twelve equal monthly tranches starting on November 26, 2025.
Ren also holds restricted share units (RSUs) linked to 28,850 Ordinary Shares, which vest in four equal increments on each of November 26, 2026, 2027, 2028 and 2029. In addition, the filing lists direct ownership of 8,964 Ordinary Shares as of the reported date, providing a clear picture of Ren’s existing economic stake and unvested awards.
ASCENTAGE PHARMA GROUP INTERNATIONAL director Ye Changqing filed an amended initial ownership report that corrects and clarifies his equity holdings. The filing shows options over 18,850 Ordinary Shares at an exercise price of $8.14 expiring on November 26, 2035, 28,850 restricted share units that vest in four equal annual installments from November 26, 2026 through 2029, and 8,964 Ordinary Shares held directly. Footnotes explain that the numbers of Ordinary Shares, share options, and vesting schedules were inadvertently reported incorrectly in the original submission.
ASCENTAGE PHARMA GROUP INTERNATIONAL filed an amended insider ownership report for director Debra Yu, updating previously reported equity awards. The amendment shows stock options over 17,965 Ordinary Shares with an exercise price of 8.1400 per share and an expiration date of November 26, 2035. These options vest in twelve equal monthly tranches on the 26th of each month starting November 26, 2025. It also reports 27,965 restricted share units, each representing one Ordinary Share that vests in four equal installments on November 26 of 2026, 2027, 2028 and 2029. A footnote states the number of share options and/or vesting was inadvertently reported incorrectly in the original submission.
Ascentage Pharma Group International director Simon Dazhong Lu filed an amended ownership report that corrects and clarifies his holdings. The filing lists options over 17,965 Ordinary Shares at an exercise price of $8.1400 expiring on November 26, 2035, vesting in twelve equal monthly tranches starting November 26, 2025. It also discloses 27,965 restricted share units, each convertible into one Ordinary Share and vesting in four equal installments on November 26 of 2026, 2027, 2028 and 2029, plus 41,457 Ordinary Shares held directly. Footnotes explain that the number of Ordinary Shares and certain option details were inadvertently misstated or omitted in the original submission.
ASCENTAGE PHARMA GROUP INTERNATIONAL director Lu Simon Dazhong filed an amended initial ownership report to correct previously reported equity holdings. The amendment clarifies that he holds options over 17,965 Ordinary Shares at an exercise price of $8.1400 expiring on November 26, 2035, 27,965 restricted share units tied to Ordinary Shares, and 41,457 Ordinary Shares directly. Footnotes state that the number of Ordinary Shares and certain option figures and vesting terms were inadvertently misstated or omitted in the original filing, and provide detailed vesting schedules for both the options and RSUs.
Ascentage Pharma Group International director David Sidransky filed an amended Form 3 to correct his reported equity holdings. The filing now shows stock options over 18,850 Ordinary Shares at an exercise price of 8.1400 expiring on November 26, 2035, vesting in twelve equal monthly tranches starting November 26, 2025. It also reflects 28,850 restricted share units that vest in four equal annual increments on November 26 of 2026, 2027, 2028 and 2029, plus 10,641 directly held Ordinary Shares. Footnotes state that prior submissions inadvertently misstated the number of Ordinary Shares and option details.
ASCENTAGE PHARMA GROUP INTERNATIONAL director Wang Shaomeng filed an initial ownership report showing a mix of direct and indirect stakes in the company’s Ordinary Shares, along with equity awards in the form of options and restricted share units.
Direct holdings include 1,193,032 Ordinary Shares, options over 17,965 Ordinary Shares at an exercise price of $8.14 per share expiring on November 26, 2035, and 27,965 restricted share units, each convertible into one Ordinary Share and scheduled to vest annually on November 26 of 2026, 2027, 2028 and 2029. Additional Ordinary Shares are held indirectly through trusts, with 2,836,845 shares held by KEW Trust and 6,024,066 shares held by Shaomeng Wang Dynasty Trust.